指南针通路

US · CMPS #2952 按市值排名上市于 2020

10.75 -0.87 -7.49%

实时 - 追踪5344个代码 - 心跳于83秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了2家。
机构持股总比例下降了2.7个百分点。

机构持股

机构持股比例: 69.90% -2.68pp
机构数量: 238 -2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Hedge Fund30.69%

Mutual Fund19.26%

VC/PE Fund10.88%

Public Company6.95%

Private Company1.87%

Individual/Insider1.64%

Endowment Fund0.15%

Other28.46%

主要股东截至 2026-06-30

Deep Track Capital, LP 8.78% · 12.16M 股

RTW Investments, LP 7.73% · 10.70M 股

BIT Capital GmbH 4.58% · 6.35M 股

Tang Capital Management, LLC 3.61% · 5.00M 股

Eli Lilly and Company 3.44% · 4.76M 股

Two Sigma Investments, LP 3.23% · 4.47M 股

Marshall Wace LLP 3.13% · 4.33M 股

ARK Investment Management LLC 2.49% · 3.45M 股

Point72 Asset Management, L.P. 1.89% · 2.62M 股

Logos Global Management, L.P. 1.62% · 2.25M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 33次买入 · 17次卖出

姓名	职务	持股比例
George Goldsmith	Chairman & Co-founder	1.48%
Thomas Lonngren	Independent Non-Executive Director	0.06%
Kabir Nath	Chief Executive Officer	0.05%
Teri Loxam	CFO, Principal Financial Officer & Principal Accounting Officer	0.02%
David Norton	Lead Independent Director	0.01%
Annalisa Lisa Jenkins	Independent Non-Executive Director	0.01%
Guy Goodwin	Chief Medical Officer	0.00%
Jeffrey Jonas	Director	--
Justin Gover	Director	--
Linda McGoldrick	Independent Non-Executive Director	--

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-09	Annalisa Lisa Jenkins	Independent Non-Executive Director	Intent to Sell (Form 144)	-26,000	$13.30
2026-08-06	Annalisa Lisa Jenkins	Independent Non-Executive Director	Intent to Sell (Form 144)	-83,771	$13.72
2026-08-02	Kabir Nath	Chief Executive Officer	Sale to Issuer	-5,962	$11.25
2026-05-26	Jeffrey Jonas	Director	Other Derivative Acquisition	+21,110	$11.85
2026-05-26	Justin Gover	Director	Other Derivative Acquisition	+21,110	$11.85
2026-05-26	Gino Santini	Chairperson	Other Derivative Acquisition	+30,158	$11.85
2026-05-26	David Norton	Lead Independent Director	Other Derivative Acquisition	+21,110	$11.85
2026-05-26	Daphne Karydas	Independent Director	Other Derivative Acquisition	+21,110	$11.85
2026-05-26	Robert McQuade	Independent Non-Executive Director	Other Derivative Acquisition	+21,110	$11.85
2026-05-26	Wayne Riley	Independent Non-Executive Director	Other Derivative Acquisition	+21,110	$11.85
2026-05-26	Kathleen Tregoning	Director	Other Derivative Acquisition	+41,119	$11.85
2026-03-25	Teri Loxam	CFO, Principal Financial Officer & Principal Accounting Officer	Other Acquisition	+75,000	--
2026-03-25	Teri Loxam	CFO, Principal Financial Officer & Principal Accounting Officer	Other Derivative Acquisition	+157,635	$5.64
2026-03-25	Kabir Nath	Chief Executive Officer	Other Acquisition	+175,000	--
2026-03-25	Kabir Nath	Chief Executive Officer	Other Derivative Acquisition	+367,815	$5.64
2026-03-25	Guy Goodwin	Chief Medical Officer	Other Derivative Acquisition	+170,600	$0.01–5.64
2026-03-10	Teri Loxam	CFO, Principal Financial Officer & Principal Accounting Officer	Sale to Issuer	-1,781	$6.89
2026-03-10	Kabir Nath	Chief Executive Officer	Sale to Issuer	-13,131	$6.89
2026-03-01	Teri Loxam	CFO, Principal Financial Officer & Principal Accounting Officer	Sale to Issuer	-4,467	$7.02
2026-02-01	Kabir Nath	Chief Executive Officer	Sale to Issuer	-16,181	$6.61

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。